Tumor cell–intrinsic PD-1 promotes Merkel cell carcinoma growth by activating downstream mTOR-mitochondrial ROS signaling

Christina Martins,Erik Rasbach,Markus V. Heppt,Praveen Singh,Zsofi Kulcsar,Julia Holzgruber,Asmi Chakraborty,Kyla Mucciarone,Sonja Kleffel,Anne Brandenburg,Wolfram Hoetzenecker,Nuh N. Rahbari,James A. DeCaprio,Manisha Thakuria,George F. Murphy,Matthew R. Ramsey,Christian Posch,Steven R. Barthel,Tobias Schatton

DOI: https://doi.org/10.1126/sciadv.adi2012

IF: 13.6

2024-01-21

Science Advances

Abstract:Merkel cell carcinoma (MCC) is a rare and aggressive skin cancer. Inhibitors targeting the programmed cell death 1 (PD-1) immune checkpoint have improved MCC patient outcomes by boosting antitumor T cell immunity. Here, we identify PD-1 as a growth-promoting receptor intrinsic to MCC cells. In human MCC lines and clinical tumors, RT-PCR–based sequencing, immunoblotting, flow cytometry, and immunofluorescence analyses demonstrated PD-1 gene and protein expression by MCC cells. MCC–PD-1 ligation enhanced, and its inhibition or silencing suppressed, in vitro proliferation and in vivo tumor xenograft growth. Consistently, MCC–PD-1 binding to PD-L1 or PD-L2 induced, while antibody-mediated PD-1 blockade inhibited, protumorigenic mTOR signaling, mitochondrial (mt) respiration, and ROS generation. Last, pharmacologic inhibition of mTOR or mtROS reversed MCC–PD-1:PD-L1–dependent proliferation and synergized with PD-1 checkpoint blockade in suppressing tumorigenesis. Our results identify an MCC–PD-1–mTOR–mtROS axis as a tumor growth–accelerating mechanism, the blockade of which might contribute to clinical response in patients with MCC.

multidisciplinary sciences